Life with SMA: challenges and solutions

Spinal muscular atrophy (SMA) is a rare genetic neuromuscular disease that affects the central nervous system, peripheral nervous system, and voluntary muscle movement. [SHUTTESTOCK/NEPO]

Despite steady advancements in the past years, gaps in Spinal Muscular Atrophy (SMA) care persist across the bloc.

SMA is a rare genetic neuromuscular disease that affects the central nervous system, peripheral nervous system, and voluntary muscle movement.

Standards of care are now available to manage symptoms and help people enjoy an optimum quality of life, but access to treatment is not the same across Europe.

In this series of articles, EURACTIV digs into policy options to ensure patients the chance to live with this rare disease.

Download PDF  

Subscribe to our newsletters

Subscribe